Development and evaluation of magnetic microemulsion: Tool for targeted delivery of camptothecin to BALB/c mice-bearing breast cancer

Journal of Drug Targeting

Volumn 22, Issue 10, 2014, Pages 913-926

  Natesan, Subramanian ^a   Sugumaran, Abimanyu ^a   Ponnusamy, Chandrasekar ^a   Jeevanesan, Vinoth ^a   Girija, Gangarani ^a   Palanichamy, Rajaguru ^a  

^a ANNA UNIVERSITY   (India)

Author keywords

4T1 breast cancer; Camptothecin; Magnetic microemulsion; Targeting potential

Indexed keywords

CAMPTOTHECIN; LACTONE; ANTINEOPLASTIC AGENT; EMULSION; POLYSORBATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; EVALUATION STUDY; GENOTOXICITY; HEMOLYSIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAGNETIC FIELD; MAGNETIC MICROEMULSION; MICROEMULSION; MOUSE; NONHUMAN; TARGET ORGAN; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CHEMISTRY; DNA DAMAGE; DRUG EFFECTS; EMULSION; FEMALE; LYMPHOCYTE; MCF 7 CELL LINE; METABOLISM; PARTICLE SIZE; PATHOLOGY; TIME; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CAMPTOTHECIN; DNA DAMAGE; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; FEMALE; HUMANS; LYMPHOCYTES; MAGNETIC FIELDS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; PARTICLE SIZE; POLYSORBATES; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84910074418     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.948878     Document Type: Article

References (51)

1. Liu LF, Desai SD, Li TK, et al. Mechanism of action of camptothecin. Ann NY Acad Sci 2000;922:1-10.
2. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003;361: 2235-42.
3. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994;86:836-42.
4. Gao Y, Li LB, Zhai G. Preparation and characterization of Pluronic/ TPGS mixed micelles for solubilization of camptothecin. Colloids Surf B Biointerfaces 2008;64:194-9.
5. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992; 81:676-84.
6. Mi Z, Burke TG. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 1994;33:10325-36.
7. Burris III HA. Topotecan: incorporating it into the treatment of solid tumors. Oncologist 1998;3:1-3.
8. Rivory LP, Robert J. Molecular, cellular, and clinical aspects of the pharmacology of 20(S) camptothecin and its derivatives. Pharmacol Ther 1995;68:269-96.
9. Watanabe M, Kawano K, Toma K, et al. In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. J Control Release 2008; 127:231-8.
10. Patankar N, Waterhouse D. Nano-particulate drug delivery systems for camptothecins. Cancer Therapy 2012;8:90-104.
11. Huang ZR, Hua SC, Yang YL, Fang JY. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin 2008;29: 1094-102.
12. Takimoto CH, Wright J, Arbuck SG. Clinical applications of the camptothecins. Biochim Biophys Acta 1998;1400:107-19.
13. Hatefi A, Amsden B. Camptothecin delivery methods. Pharm Res 2002;19:1389-99.
14. Mason TG, Wilking JN, Meleson K, et al. Nanoemulsions: formation, structure, and physical properties. J Phys Condens Matter 2006;18:R635.
15. Chen H, Khemtong C, Yang X, et al. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today 2011;16:354-60.
16. Bansal SS, Goel M, Aqil F, et al. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (Phila) 2011;4:1158-71.
17. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998;95:4607-12.
18. Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 2009;6:928-39.
19. Shafiq-un-Nabi S, Shakeel F, Talegaonkar S, et al. Formulation development and optimization using nanoemulsion technique: a technical note. AAPS PharmSciTech 2007;8:E12-17.
20. Thapa D, Palkar VR, Kurup MB, Malik SK. Properties of magnetite nanoparticles synthesized through a novel chemical route. Mater Lett 2004;58:2692-4.
21. Yang X, Hu Z, Chan SY, et al. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat. J Chromatogr B 2005;821:221-8.
22. Zhai Y, Guo S, Liu C, et al. Preparation and in vitro evaluation of apigenin-loaded polymeric micelles. Colloid Surf A 2013;429: 24-30.
23. Katas H, Hussain Z, Ling TC. Chitosan nanoparticles as a percutaneous drug delivery system for hydrocortisone. J Nanomater 2012;2012:1-11.
24. Amin K, Dannenfelser RM. In vitro hemolysis: guidance for the pharmaceutical scientist. J Pharm Sci 2006;95:1173-6.
25. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:184-91.
26. Conover CD, Greenwald RB, Pendri A, et al. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother Pharmacol 1998;42:407-14.
27. Martins SM, Wendling T, Gonçalves VM, et al. Development and validation of a simple reversed-phase HPLC method for the determination of camptothecin in animal organs following administration in solid lipid nanoparticles. J Chromatogr B 2012;880: 100-7.
28. Sarker DK. Engineering of nanoemulsions for drug delivery. Curr Drug Deliv 2005;2:297-310.
29. Wang L, Dong J, Chen J, et al. Design and optimization of a new self-nanoemulsifying drug delivery system. J Colloid Interface Sci 2009;330:443-8.
30. Yalkowsky SH, Krzyzaniak JF, Ward GH. Formulation-related problems associated with intravenous drug delivery. J Pharm Sci 1998;87:787-96.
31. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys 2003; 36:R167-81.
32. Werbovetz KA, Bhattacharjee AK, Brendle JJ, Scovill JP. Analysis of stereoelectronic properties of camptothecin analogues in relation to biological activity. Bioorg Med Chem 2000; 8:1741-7.
33. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 2004;56: 827-40.
34. Lee BS, Nalla AK, Stock IR, et al. Oxidative stimuli-responsive nanoprodrug of camptothecin kills glioblastoma cells. Bioorg Med Chem Lett 2010;20:5262-8.
35. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004;21:201-30.
36. Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. J Pharm Sci 2007;96: 3155-67.
37. Simamora P, Alvarez JM, Yalkowsky SH. Solubilization of rapamycin. Int J Pharm 2001;213:25-9.
38. Fabiano V, Mameli C, Zuccotti GV. Paediatric pharmacology: remember the excipients. Pharmacol Res 2011;63:362-5.
39. Cinelli MA, Morrell A, Dexheimer TS, et al. Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors. J Med Chem 2008;51:4609-19.
40. Collnot EM, Baldes C, Wempe MF, et al. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm 2007;4: 465-74.
41. Warisnoicharoen W, Lansley AB, Lawrence MJ. Nonionic oil-inwater microemulsions: the effect of oil type on phase behaviour. Int J Pharm 2000;198:7-27.
42. Benita S, Levy MY. Submicron emulsions as colloidal drug carriers for intravenous administration: comprehensive physicochemical characterization. J Pharm Sci 1993;2:1069-79.
43. He W, Tan Y, Tian Z, et al. Food protein-stabilized nanoemulsions as potential delivery systems for poorly water-soluble drugs: preparation, in-vitro characterization, and pharmacokinetics in rats. Int J Nanomedicine 2011;6:521-33.
44. Tadros T, Izquierdo P, Esquena J, Solans C. Formation and stability of nano-emulsions. Adv Colloid Interface Sci 2004;108-109: 303-18.
45. Tamilvanan S, Schmidt S, Müller RH, Benita S. In-vitro adsorption of plasma proteins onto the surface (charges) modified-submicron emulsions for intravenous administration. Eur J Pharm Biopharm 2005;59:1-7.
46. Mu L, Seow PH. Application of TPGS in polymeric nanoparticulate drug delivery system. Colloids Surf B Biointerfaces 2006;47:90-7.
47. Torchilin VP, Trubetskoy VS. Which polymers can make nanoparticulate drug carriers long-circulating. Adv Drug Deliv Rev 1995;16:141-55.
48. Bahadur D, Giri J. Biomaterials and magnetism. Sadhana 2003;28: 639-56.
49. Hu FX, Neoh KG, Kang ET. Synthesis and in-vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. Biomaterials 2006;27:5725-33.
50. Krzynzaniak JF, Alvarez Nunez FA, Raymond DM, Yalkowsky SH. Lysis of human red blood cells. 4. Comparison of in-vitro and invivo hemolysis data. J Pharm Sci 1997;86:1215-17.
51. Mu L, Elbayoumi TA, Torchilin VP. Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and Da-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin. Int J Pharm 2005;306:142-9.